Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAI-7535 PK study in obesity or overweight
NCT07294898Phase 1Completed
- Sponsor
- Kailera Therapeutics
- Start
- Dec 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HRS-7535 in obesity (3 arms), sponsored by Kailera Therapeutics. Primary endpoints: Time to Maximum Observed Concentration at 60 hours, Maximum Observed Concentration at 60 hours and 2 more. Started Dec 2025; status: completed.
02
Drugs
HRS-7535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07294898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294898.